ONCY News and Press, Oncolytics Biotech Inc. From 03/31/22

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial Canada NewsWire Independent review identified, no safety concerns in trial's final safety run-...

Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor for the global market. As more and more patients are diag...

Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort Canada NewsWire First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated ...

Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity New insights into pelareorep's immune-related mechanism of action demonstrate it stimulates an innate immune response...

Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting Canada NewsWire - Prolonged progression-free survival of >3 years a...

Oncolytics Biotech, Inc. (ONCY) Q4 2021 Earnings Conference Call March 03, 2022, 17:00 ET Company Participants Jon Patton - Director, IR & Communication Matthew Coffey - President, CEO & Director Thomas Heineman - Chief Medical Officer Kirk Look - CFO Andrew de Guttadauro - Global Hea...

Oncolytics Biotech press release (NASDAQ:ONCY): Q4 GAAP EPS of -C$0.14. Net cash used in operating activities was C$22.4 million for the full year 2021, compared to C$22.1 million for the full year 2020. As of December 31, 2021, the company reported C$41.3 million in cash and cash equivalents...

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights Canada NewsWire Randomized phase 2 metastatic breast cancer trial (BRACELET-1) on track for top-line data in Q4 2022 Clinical breast cancer da...

ACR, AQN, AVAV, AVGO, BCEL, CEMI, CLLS, CLXT, COO, COST, OTCPK:CURLF, DBVT, DUOL, EGLE, ENVX, EOLS, ESTC, EVFM, FCRD, FDUS, FNKO, GPS, INMB, OTCPK:MEGEF, MRVL, NCMI, ONCY, PAYO, PBYI, SIGA, SWBI, VERI, VZIO For Seeking Alpha's full earnings season calendar, click here. For further details s...

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights Conference call and webcast to take place on Thursday, March 3, 2022, at 5:00 p.m. ET PR Newswire SAN DIEGO, Calif. and ...